EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

NCT02154399 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Stage IA Non-Small Cell Lung Carcinoma
Stage IB Non-Small Cell Lung Carcinoma
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIB Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer

Interventions

DRUG: EF5
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Therapeutic Conventional Surgery
OTHER: Tissue Oxygen Measurement

Sponsor

National Cancer Institute (NCI)